BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 30029633)

  • 1. Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival.
    Lee M; Tayyari F; Pinnaduwage D; Bayani J; Bartlett JMS; Mulligan AM; Bull SB; Andrulis IL
    BMC Cancer; 2018 Jul; 18(1):750. PubMed ID: 30029633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer.
    Mulligan AM; Pinnaduwage D; Tchatchou S; Bull SB; Andrulis IL
    Cancer Immunol Res; 2016 Jan; 4(1):41-8. PubMed ID: 26546451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-box transcription factor 21 expression in breast cancer and its relationship with prognosis.
    Yu H; Yang J; Jiao S; Li Y; Zhang W; Wang J
    Int J Clin Exp Pathol; 2014; 7(10):6906-13. PubMed ID: 25400774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 Regulates Breast Cancer Dissemination through Jagged1/Notch1 Signaling.
    Andrieu G; Tran AH; Strissel KJ; Denis GV
    Cancer Res; 2016 Nov; 76(22):6555-6567. PubMed ID: 27651315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
    Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
    Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
    Shou J; Zhang Z; Lai Y; Chen Z; Huang J
    BMC Cancer; 2016 Aug; 16(1):687. PubMed ID: 27566250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain 4 is a potent prognostic marker associated with immune cell infiltration in breast cancer.
    Zhong L; Yang Z; Lei D; Li L; Song S; Cao D; Liu Y
    Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):169-182. PubMed ID: 32799413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher numbers of T-bet(+) intratumoral lymphoid cells correlate with better survival in gastric cancer.
    Chen LJ; Zheng X; Shen YP; Zhu YB; Li Q; Chen J; Xia R; Zhou SM; Wu CP; Zhang XG; Lu BF; Jiang JT
    Cancer Immunol Immunother; 2013 Mar; 62(3):553-61. PubMed ID: 23090288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
    Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
    Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
    Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
    Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Wu J; Li X; Teng X; Rubin DL; Napel S; Daniel BL; Li R
    Breast Cancer Res; 2018 Sep; 20(1):101. PubMed ID: 30176944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.
    Lee HJ; Kim A; Song IH; Park IA; Yu JH; Ahn JH; Gong G
    Pathol Int; 2016 Apr; 66(4):202-9. PubMed ID: 26922571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Srivastava AN; Makker A; Goel MM
    Indian J Cancer; 2013; 50(3):239-44. PubMed ID: 24061465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.